Does the media prefer LGVN or PMVP?

In the previous week, Longeveron had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for PMV Pharmaceuticals. Longeveron's average media sentiment score of 0.97 beat PMV Pharmaceuticals' score of 0.94 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFC or LGVN?

Longeveron has a consensus target price of $5.50, indicating a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better valuation & earnings, AIFC or LGVN?

Longeveron has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 2.44 -$344.51M N/A N/A Longeveron $1.20M 15.58 -$22.70M -$1.13 N/A

Is AIFC or LGVN more profitable?

Longeveron has a net margin of -1,844.49% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% Longeveron -1,844.49% -202.41% -140.67%

Do analysts rate LGVN or SCLX?

Longeveron currently has a consensus target price of $5.50, suggesting a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts clearly believe Longeveron is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, LGVN or SCLX?

Longeveron has higher earnings, but lower revenue than Scilex. Longeveron is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Longeveron $1.20M 15.58 -$22.70M -$1.13 N/A Scilex $30.25M 1.92 -$358.73M -$40.47 N/A

Is LGVN or SCLX more profitable?

Scilex has a net margin of -1,110.17% compared to Longeveron's net margin of -1,844.49%. Scilex's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,844.49% -202.41% -140.67% Scilex -1,110.17% N/A -143.55%

Does the media refer more to LGVN or SCLX?

In the previous week, Longeveron had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Scilex. Scilex's average media sentiment score of 1.25 beat Longeveron's score of 0.97 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LGVN or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Talphera's return on equity of -92.98% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,844.49% -202.41% -140.67% Talphera N/A -92.98% -53.22%

Does the media prefer LGVN or TLPH?

In the previous week, Longeveron had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Talphera. Talphera's average media sentiment score of 1.23 beat Longeveron's score of 0.97 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATRA or LGVN?

In the previous week, Longeveron had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.32 beat Longeveron's score of 0.97 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Longeveron (LGVN) Competitors

$0.60 -0.01 (-1.19%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.50%)

As of 07/24/2026 06:20 PM Eastern

Compare

LGVN vs. PMVP, AIFC, SCLX, TLPH, and ATRA

Should you buy Longeveron stock or one of its competitors? MarketBeat compares Longeveron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longeveron include PMV Pharmaceuticals (PMVP), ALT5 Sigma (AIFC), Scilex (SCLX), Talphera (TLPH), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Longeveron compare to PMV Pharmaceuticals?

Longeveron (NASDAQ:LGVN) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Longeveron had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for PMV Pharmaceuticals. Longeveron's average media sentiment score of 0.97 beat PMV Pharmaceuticals' score of 0.94 indicating that Longeveron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Longeveron currently has a consensus price target of $5.50, indicating a potential upside of 816.67%. PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 222.58%. Given Longeveron's higher possible upside, analysts plainly believe Longeveron is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Longeveron has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

PMV Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. PMV Pharmaceuticals' return on equity of -68.98% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

10.0% of Longeveron shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Longeveron has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	15.58	-$22.70M	-$1.13	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats Longeveron on 8 of the 15 factors compared between the two stocks.

How does Longeveron compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Longeveron (NASDAQ:LGVN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Longeveron has a consensus target price of $5.50, indicating a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Longeveron had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for Longeveron and 1 mentions for ALT5 Sigma. Longeveron's average media sentiment score of 0.97 beat ALT5 Sigma's score of 0.94 indicating that Longeveron is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Longeveron	Positive

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Longeveron has a net margin of -1,844.49% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Longeveron	-1,844.49%	-202.41%	-140.67%

ALT5 Sigma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Longeveron has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	2.44	-$344.51M	N/A	N/A
Longeveron	$1.20M	15.58	-$22.70M	-$1.13	N/A

Summary

Longeveron beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does Longeveron compare to Scilex?

Longeveron (NASDAQ:LGVN) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Longeveron had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Scilex. Scilex's average media sentiment score of 1.25 beat Longeveron's score of 0.97 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Longeveron has higher earnings, but lower revenue than Scilex. Longeveron is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	15.58	-$22.70M	-$1.13	N/A
Scilex	$30.25M	1.92	-$358.73M	-$40.47	N/A

10.0% of Longeveron shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Scilex has a net margin of -1,110.17% compared to Longeveron's net margin of -1,844.49%. Scilex's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Scilex	-1,110.17%	N/A	-143.55%

Longeveron has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market. Comparatively, Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Longeveron currently has a consensus target price of $5.50, suggesting a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts clearly believe Longeveron is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Longeveron beats Scilex on 9 of the 16 factors compared between the two stocks.

How does Longeveron compare to Talphera?

Longeveron (NASDAQ:LGVN) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 7.4% of Longeveron shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Talphera has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Talphera's return on equity of -92.98% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Talphera	N/A	-92.98%	-53.22%

Talphera has lower revenue, but higher earnings than Longeveron. Talphera is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	15.58	-$22.70M	-$1.13	N/A
Talphera	$30K	2,335.50	-$14.29M	-$0.31	N/A

Longeveron presently has a consensus price target of $5.50, suggesting a potential upside of 816.67%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 122.22%. Given Longeveron's higher possible upside, research analysts plainly believe Longeveron is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Longeveron has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market. Comparatively, Talphera has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, Longeveron had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Talphera. Talphera's average media sentiment score of 1.23 beat Longeveron's score of 0.97 indicating that Talphera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Talphera beats Longeveron on 9 of the 13 factors compared between the two stocks.

How does Longeveron compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Atara Biotherapeutics has higher revenue and earnings than Longeveron. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.59	$32.69M	-$0.67	N/A
Longeveron	$1.20M	15.58	-$22.70M	-$1.13	N/A

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential upside of 20.25%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Atara Biotherapeutics has a net margin of -40.91% compared to Longeveron's net margin of -1,844.49%. Atara Biotherapeutics' return on equity of -79.12% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Longeveron	-1,844.49%	-202.41%	-140.67%

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

In the previous week, Longeveron had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.32 beat Longeveron's score of 0.97 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atara Biotherapeutics beats Longeveron on 10 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.69M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.53	21.48	27.14	23.64
Price / Sales	15.58	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.40	7.88	10.28	6.07
Net Income	-$22.70M	$23.86M	$3.60B	$331.99M
7 Day Performance	-3.54%	-3.82%	-1.27%	-0.63%
1 Month Performance	-17.70%	-2.61%	-0.37%	-2.00%
1 Year Performance	-64.07%	32.79%	18.30%	13.62%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	2.3188 of 5 stars	$0.60 -1.2%	$5.50 +816.7%	-64.5%	$18.69M	$1.20M	N/A	20	News Coverage
PMVP PMV Pharmaceuticals	3.698 of 5 stars	$1.42 +10.9%	$4.00 +181.7%	-13.9%	$75.73M	N/A	N/A	50	News Coverage High Trading Volume
AIFC ALT5 Sigma	0.4296 of 5 stars	$0.54 +1.5%	N/A	-93.9%	$75.29M	$24.84M	N/A	170	News Coverage
SCLX Scilex	1.0505 of 5 stars	$8.76 -7.2%	N/A	-36.2%	$74.37M	$30.25M	N/A	80	Positive News
TLPH Talphera	3.0877 of 5 stars	$1.41 -1.1%	$3.00 +113.5%	+215.2%	$72.92M	$1K	N/A	19	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. PMVP, AIFC, SCLX, TLPH, and ATRA

How does Longeveron compare to PMV Pharmaceuticals?

Summary

How does Longeveron compare to ALT5 Sigma?

Summary

How does Longeveron compare to Scilex?

Summary

How does Longeveron compare to Talphera?

Summary

How does Longeveron compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. PMVP, AIFC, SCLX, TLPH, and ATRA

How does Longeveron compare to PMV Pharmaceuticals?

Does the media prefer LGVN or PMVP?

Do analysts prefer LGVN or PMVP?

Which has more risk and volatility, LGVN or PMVP?

Is LGVN or PMVP more profitable?

Do insiders & institutionals have more ownership in LGVN or PMVP?

Which has stronger earnings & valuation, LGVN or PMVP?

Summary

How does Longeveron compare to ALT5 Sigma?

Do analysts recommend AIFC or LGVN?

Does the media favor AIFC or LGVN?

Do insiders and institutionals believe in AIFC or LGVN?

Is AIFC or LGVN more profitable?

Which has more risk & volatility, AIFC or LGVN?

Which has better valuation & earnings, AIFC or LGVN?

Summary

How does Longeveron compare to Scilex?

Does the media refer more to LGVN or SCLX?

Which has preferable valuation and earnings, LGVN or SCLX?

Do insiders & institutionals hold more shares of LGVN or SCLX?

Is LGVN or SCLX more profitable?

Which has more risk & volatility, LGVN or SCLX?

Do analysts rate LGVN or SCLX?

Summary

How does Longeveron compare to Talphera?

Do institutionals and insiders hold more shares of LGVN or TLPH?

Is LGVN or TLPH more profitable?

Which has better earnings & valuation, LGVN or TLPH?

Do analysts rate LGVN or TLPH?

Which has more risk and volatility, LGVN or TLPH?

Does the media prefer LGVN or TLPH?

Summary

How does Longeveron compare to Atara Biotherapeutics?

Which has stronger valuation and earnings, ATRA or LGVN?

Do analysts prefer ATRA or LGVN?

Is ATRA or LGVN more profitable?

Do institutionals and insiders have more ownership in ATRA or LGVN?

Which has more volatility and risk, ATRA or LGVN?

Does the media favor ATRA or LGVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools